PRINCETON, N.J. Nov. 7, 2017—WCG Foundation has received $50,000 from Johnson & Johnson to help desperately ill patients get access to experimental medicines.
The gift supports WCGF’s efforts to help patients navigate the Food and Drug Administration’s expanded access program, which makes investigational drugs available to patients who have exhausted all other treatment and clinical trial options.Learn More >
WCGF Director David Farber, JD provides expertise in NPR’s 1A Discussion of Expanded Access and Senate Right-To-Try Legislation
David Farber, Partner in the FDA and Life Sciences practice of the law firm King and Spalding, and a Director of WCGF lent his expertise to a nuanced discussion of the questions surrounding expanded access to experimental drugs for patients seeking drugs outside of clinical trials. The program, which provided multiple views on state Right-To-Try legislation as well as the Senate’s recent passing of federal Right to Try legislation, aired on NPR’s 1A program on August 7, 2017.
You can listen to the complete program at:
Pfizer Grant Helps WCG Foundation Identify Obstacles to Expanded Access
WCG Foundation Progress Report, January 25, 2017
WCG Foundation (WCGF) has received a $5,000 grant from Pfizer to identify obstacles that could discourage physicians from helping desperately ill patients who want to access investigational drugs.
The grant is the latest to support WCGF’s Expanded Access Project, which helps those who have exhausted all treatment and clinical trial options and want the chance to try experimental medicines. Learn more.
GlaxoSmithKline Grant Supports WCGF Expanded Access Project
WCG Foundation Progress Report, January 24, 2017
WCG Foundation (WCGF) has received $15,000 from GlaxoSmithKline (GSK) for the Foundation’s Expanded Access Project. The project helps desperately ill patients who have exhausted all treatment and clinical trial options and want to try experimental medicines.
WCGF will use the GSK grant to help institutional review boards (IRB) streamline the process that patients must navigate to gain access to investigational drugs and devices. Learn more.
$100,000 Grant from Robert Wood Johnson Foundation Supports WCGF Expanded Access Program
WCG Foundation Progress Report, October 31, 2016
WCG Foundation (WCGF) has received $100,000 from the Robert Wood Johnson Foundation (RWJF) to support WCGF’s new Expanded Access Project. The grant targets physicians and institutional review boards (IRBs), who play key roles in helping desperately ill patients gain access to experimental medicines.
Launched in July, the Expanded Access Project seeks to streamline the process for those seeking Food and Drug Administration (FDA) approval to try investigational drugs and devices. The goal is to make the process less burdensome and more equitable and transparent. Learn more.
First WCGF Grant Funds Innovative Research Ethics Curriculum at NYU
WCG Foundation Progress Report, August 17, 2016
WCG Foundation’s (WCGF’s) first grant—a two-year $200,000 award to New York University (NYU)—has already enabled NYU Langone Medical Center (NYULMC) to strengthen research ethics education within and beyond the medical center. During the first year, NYU funded curriculum development and supported faculty participation in lectures, webinars, panel discussions, and other outreach efforts.
As a result, 20 students at NYULMC completed a new course in research ethics and integrity, and 12 research professionals from resource-poor countries attended a two-week intensive ethics training program. In addition, thousands of students and faculty from the nation’s top academic institutions and high schools gained a better understanding of today’s research ethics issues through webinars, lectures, and publications. Learn more.
Foundation Seeks IRBs to Review Single-Patient Expanded Access Applications
WCG Foundation RFP, July 28, 2016
WCG Foundation (WCGF) has issued a request for proposals (RFP) to pilot an expanded access program. The Foundation wishes to engage several organizations with institutional review boards (IRBs) to conduct full board reviews of single-patient expanded access (compassionate use) applications. Details are available in the RFP.
Deadline to respond is 5 p.m. EDT August 29.